Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

2(29%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

43%

Ph phase_2

43%

Ph phase_3

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

3(42.9%)

Phase 2Efficacy & side effects

3(42.9%)

Phase 3Large-scale testing

1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Withdrawn1

Active, not recruiting1

Recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (42.9%)

Phase 23 (42.9%)

Phase 31 (14.3%)

Trials by Status

withdrawn114%

active_not_recruiting114%

completed343%

recruiting114%

not_yet_recruiting114%

Recent Activity

2 active trials

Showing 5 of 7

recruitingphase_2

A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

NCT07615010

active_not_recruitingphase_2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

NCT06251973

withdrawnphase_3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

NCT07492875

not_yet_recruitingphase_2

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

NCT07550088

completedphase_1

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

NCT04582201

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT07615010Phase 2

A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

Recruiting

NCT06251973Phase 2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Active Not Recruiting

NCT07492875Phase 3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Withdrawn

NCT07550088Phase 2

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

Not Yet Recruiting

NCT04582201Phase 1

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

Completed

NCT05108623Phase 1

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors